Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

RAV12

Monoclonal antibody · Kills target cells, directed at primate-restricted N-linked carbohydrate epitope (glycotope) on human carcinomas · developed by MacroGenics

Phase 2 Most advanced trial (none active)
MGNX Developer
2 Registered trials

What is RAV12?

RAV12 is a chimeric monoclonal antibody that binds a primate-restricted N-linked carbohydrate epitope expressed on various human carcinomas. After binding, it disrupts sodium channels of the tumor cells, causing cell and organelle swelling and cell death. It has been studied in cancers including pancreatic cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Monoclonal antibody
Targets
primate-restricted N-linked carbohydrate epitope (glycotope) on human carcinomas
Mechanism
Kills target cells, directed at primate-restricted N-linked carbohydrate epitope (glycotope) on human carcinomas
Pathways
sodium channel disruption, tumor cell swelling and loss of membrane integrity
Therapy area
Oncology
Developer
MacroGenics (MGNX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00625586 Phase 2 Pancreatic Cancer Terminated MGNX
NCT00101972 Phase 1 Cancer Completed MGNX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

CancerPancreatic Cancer

More from MacroGenics

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the MGNX page.

Follow MGNX, the company behind RAV12

See MGNX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MGNX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.